{"id":4493,"date":"2026-04-07T16:00:06","date_gmt":"2026-04-07T20:00:06","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/"},"modified":"2026-09-24T00:05:31","modified_gmt":"2026-09-24T04:05:31","slug":"gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/","title":{"rendered":"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 7 avril 2026, 18h00 CET <\/strong>\u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie et les revenus de son programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Situation de tr\u00e9sorerie au 31 mars 2026<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La tr\u00e9sorerie et les \u00e9quivalents de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9levaient \u00e0 3,2\u00a0millions d\u2019euros au 31\u00a0mars 2026, contre 2,4\u00a0millions d\u2019euros au 31\u00a0d\u00e9cembre 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La consommation de tr\u00e9sorerie d\u2019exploitation au premier trimestre 2026 refl\u00e8te principalement la pr\u00e9paration et la gestion des programmes d\u2019acc\u00e8s compassionnel pour GS010, notamment en France, ainsi que la pr\u00e9paration de l\u2019\u00e9tude de Phase III RECOVER, pour GS010\/LUMEVOQ<sup>\u00ae<\/sup>, la th\u00e9rapie g\u00e9nique de GenSight Biologics dans la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL).<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le 10\u00a0mars 2026, la Soci\u00e9t\u00e9 a lev\u00e9 pr\u00e8s de 1,7\u00a0million d\u2019euros sous forme d\u2019actions et de bons de souscription, y compris des bons de souscription pr\u00e9financ\u00e9s. L\u2019objectif de cette lev\u00e9e de fonds \u00e9tait de fournir \u00e0 la Soci\u00e9t\u00e9 une r\u00e9serve de tr\u00e9sorerie pour absorber d\u2019\u00e9ventuels retards de paiement du syst\u00e8me hospitalier fran\u00e7ais.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c0 la suite de <a href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/03\/09\/gensight-biologics-fait-le-point-sur-les-programmes-dacces-precoce-de-gs010-lumevoq-et-sur-letude-revise-en-cours\/\">l\u2019autorisation en mars des premi\u00e8res demandes nominatives<\/a> en France, un premier groupe de patients du programme d\u2019AAC GS010 a \u00e9t\u00e9 trait\u00e9 \u00e0 l\u2019H\u00f4pital national des 15-20 \u00e0 Paris dans le courant du m\u00eame mois.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les premiers revenus du programme d\u2019AAC ont \u00e9t\u00e9 enregistr\u00e9s en mars 2026 et se sont \u00e9lev\u00e9s \u00e0 2,6\u00a0millions d\u2019euros.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c0 la suite de la r\u00e9forme de juillet 2021 en France (D\u00e9cret n\u00b0 2021-869 du 30 juin 2021 relatif aux autorisations d\u2019acc\u00e8s pr\u00e9coce et compassionnel), les entreprises sont tenues d\u2019effectuer des versements calcul\u00e9s sur la base des indemnit\u00e9s per\u00e7ues au cours d\u2019une ann\u00e9e civile selon un bar\u00e8me de remises progressif, ces versements \u00e9tant exigibles en novembre de l\u2019ann\u00e9e suivante. En cons\u00e9quence, la Soci\u00e9t\u00e9 sera tenue de payer une remise en novembre 2027 sur la base des revenus re\u00e7us au titre du programme d\u2019acc\u00e8s compassionnel fran\u00e7ais de 2026 uniquement, qui devrait se situer entre 10\u00a0% et 35\u00a0%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les revenus devant \u00eatre enregistr\u00e9s dans les \u00e9tats financiers de la Soci\u00e9t\u00e9 sont \u00e9galement soumis \u00e0 une remise potentielle payable lors de la commercialisation du m\u00e9dicament.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le prix du traitement dans le cadre du programme d\u2019AAC pour GS010\/LUMEVOQ<sup>\u00ae<\/sup> a \u00e9t\u00e9 fix\u00e9 \u00e0 425\u00a0000\u00a0\u20ac par injection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u2019autres traitements sont programm\u00e9s pour avril 2026, et la Soci\u00e9t\u00e9 pr\u00e9voit \u00e9galement de lancer le programme payant d\u2019acc\u00e8s pr\u00e9coce en Isra\u00ebl au deuxi\u00e8me trimestre 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Horizon de tr\u00e9sorerie<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bien que la Soci\u00e9t\u00e9 ne soit pas en mesure de pr\u00e9voir le calendrier pr\u00e9cis des traitements et des paiements associ\u00e9s dans le cadre de ses diff\u00e9rents programmes d\u2019acc\u00e8s compassionnel (en particulier en France et en Isra\u00ebl) au cours de l\u2019ann\u00e9e \u00e0 venir, la Direction estime actuellement que les revenus cumul\u00e9s de ces programmes en 2026 devraient \u00eatre suffisants pour couvrir les charges d\u2019exploitation sur cette p\u00e9riode, \u00e0 l\u2019exclusion des co\u00fbts li\u00e9s au nouvel essai clinique de Phase III RECOVER, y compris certains co\u00fbts de fabrication li\u00e9s \u00e0 l\u2019\u00e9tude.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Agenda financier<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics tiendra son Assembl\u00e9e G\u00e9n\u00e9rale Annuelle le 19\u00a0mai 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> GS010\/LUMEVOQ<sup>\u00ae <\/sup>n\u2019a pas encore obtenu d\u2019autorisation de mise sur le march\u00e9 en France ni dans aucun autre pays ; il n\u2019est donc pas disponible dans le commerce.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 7 avril 2026, 18h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie et les revenus de son programme d\u2019Autorisation [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73],"news-type":[74,80],"post-year":[],"class_list":["post-4493","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-type-product-candidates","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 7 avril 2026, 18h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie et les revenus de son programme d\u2019Autorisation [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T20:00:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:31+00:00\" \/>\n<meta name=\"author\" content=\"Arthus Moulin-Fournier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Arthus Moulin-Fournier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/\"},\"author\":{\"name\":\"Arthus Moulin-Fournier\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"headline\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026\",\"datePublished\":\"2026-04-07T20:00:06+00:00\",\"dateModified\":\"2026-09-24T04:05:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/\"},\"wordCount\":663,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/\",\"name\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-04-07T20:00:06+00:00\",\"dateModified\":\"2026-09-24T04:05:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/04\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\",\"name\":\"Arthus Moulin-Fournier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"caption\":\"Arthus Moulin-Fournier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026 - GenSight Biologics","og_description":"Paris, France, le 7 avril 2026, 18h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie et les revenus de son programme d\u2019Autorisation [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/","og_site_name":"GenSight Biologics","article_published_time":"2026-04-07T20:00:06+00:00","article_modified_time":"2026-09-24T04:05:31+00:00","author":"Arthus Moulin-Fournier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Arthus Moulin-Fournier","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/"},"author":{"name":"Arthus Moulin-Fournier","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"headline":"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026","datePublished":"2026-04-07T20:00:06+00:00","dateModified":"2026-09-24T04:05:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/"},"wordCount":663,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/","name":"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-04-07T20:00:06+00:00","dateModified":"2026-09-24T04:05:31+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/04\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-et-les-revenus-du-programme-dautorisation-dacces-compassionnel-aac-au-31-mars-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie sa situation de tr\u00e9sorerie et les revenus du programme d\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) au 31 mars 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18","name":"Arthus Moulin-Fournier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","caption":"Arthus Moulin-Fournier"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4493"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4493\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4493"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4493"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4493"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4493"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}